The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global veterinary infectious disease diagnostics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Farm and companion animals are commonly exposed to diseases that can spread to humans and cause zoonotic diseases. As a result, various veterinary infectious disease diagnostic technologies are used to evaluate the health of animals, detect diseases, provide effective treatment, and reduce the risk of cross-contamination. These technologies generally include cytology, bacteriological culture, immunohistochemical stains, fecal examination, and nucleic acid amplification. They are cost-effective, easy to use and have high-throughput detection capabilities. Furthermore, with the advent of molecular diagnostics, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), microarrays, and sequencing technologies, the characterization of new, unknown viruses can be achieved.
The rising trend of nuclear families and inflating income levels are significantly contributing to the adoption of companion animals and influencing pet ownership and humanization worldwide. This represents one of the key factors fueling the market growth. Moreover, the increasing sales of pet insurance on account of the growing concerns among pet parents about the well-being of their pets is catalyzing the demand for veterinary diagnostics to detect infectious diseases. Besides this, the increasing consumption of animal-derived products around the world, along with rising concerns about food safety and the growing instances of zoonotic diseases among animals, is driving the market. Veterinary infectious disease diagnostics services monitor the health of agricultural animals and prevent human exposure to diseases. This, along with the spread of coronavirus disease (COVID-19) across the globe, has resulted in considerable growth in PCR testing to analyze the effect of the infection in animals. Apart from this, governing agencies of numerous countries are supporting veterinary practices and commercial animal-production programs, which is promoting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global veterinary infectious disease diagnostics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on technology, animal type, infection type and end user.
Breakup by Technology:
Breakup by Animal Type:
Breakup by Infection Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Biomérieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc and Virbac.
|Base Year of the Analysis||2020|
|Segment Coverage||Technology, Animal Type, Infection Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Biomérieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc and Virbac.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at